Morgan Stanley
FULC icon

Morgan Stanley’s Fulcrum Therapeutics FULC Stock Holding History

Morgan Stanley’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$674K Buy
184,192
+10,855
+6% +$66K ﹤0.01% 5414
2026
Q1 		$1.33M Buy
173,337
+7,714
+5% +$71.6K ﹤0.01% 5003
2025
Q4 		$1.87M Sell
165,623
-78,212
-32% -$796K ﹤0.01% 4857
2025
Q3 		$2.24M Sell
243,835
-70,575
-22% -$511K ﹤0.01% 4701
2025
Q2 		$2.16M Buy
314,410
+28,811
+10% +$154K ﹤0.01% 4650
2025
Q1 		$823K Sell
285,599
-1,246,133
-81% -$4.58M ﹤0.01% 5098
2024
Q4 		$7.2M Buy
1,531,732
+1,181,047
+337% +$4.36M ﹤0.01% 3676
2024
Q3 		$1.25M Sell
350,685
-884,128
-72% -$6.56M ﹤0.01% 4912
2024
Q2 		$7.66M Buy
1,234,813
+77,676
+7% +$588K ﹤0.01% 3534
2024
Q1 		$10.9M Sell
1,157,137
-61,922
-5% -$553K ﹤0.01% 3281
2023
Q4 		$8.23M Buy
1,219,059
+307,188
+34% +$1.36M ﹤0.01% 3514
2023
Q3 		$4.05M Sell
911,871
-192,003
-17% -$839K ﹤0.01% 3899
2023
Q2 		$3.64M Sell
1,103,874
-58,494
-5% -$172K ﹤0.01% 3992
2023
Q1 		$3.31M Sell
1,162,368
-11,243
-1% -$101K ﹤0.01% 4108
2022
Q4 		$8.54M Sell
1,173,611
-26,691
-2% -$174K ﹤0.01% 3228
2022
Q3 		$9.71M Buy
1,200,302
+21,346
+2% +$153K ﹤0.01% 3014
2022
Q2 		$5.78M Buy
1,178,956
+70,532
+6% +$689K ﹤0.01% 3629
2022
Q1 		$26.2M Buy
1,108,424
+1,018,874
+1,138% +$14.4M ﹤0.01% 1836
2021
Q4 		$1.58M Buy
89,550
+4,539
+5% +$89.9K ﹤0.01% 4748
2021
Q3 		$2.4M Buy
85,011
+12,715
+18% +$241K ﹤0.01% 4414
2021
Q2 		$757K Buy
72,296
+4,491
+7% +$45.4K ﹤0.01% 5247
2021
Q1 		$799K Sell
67,805
-31,093
-31% -$384K ﹤0.01% 4863
2020
Q4 		$1.16M Buy
98,898
+67,249
+212% +$760K ﹤0.01% 4579
2020
Q3 		$251K Sell
31,649
-9,401
-23% -$113K ﹤0.01% 4987
2020
Q2 		$751K Buy
41,050
+11,902
+41% +$187K ﹤0.01% 4375
2020
Q1 		$348K Buy
29,148
+15,532
+114% +$248K ﹤0.01% 4584
2019
Q4 		$226K Buy
13,616
+10,163
+294% +$97.1K ﹤0.01% 5363
2019
Q3 		$23K Buy
+3,453
New +$38.2K ﹤0.01% 5963

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley's FULC Position: Q2 2026 in Review

Morgan Stanley increased its Fulcrum Therapeutics (FULC) stake by 6.3% in Q2 2026, buying an estimated $66K and bringing the position to 184,192 shares worth $674K. The position accounts for ﹤0.01% of the portfolio, ranked #5414.

Morgan Stanley first reported a position in FULC in Q3 2019 and has held it in 28 quarters since. The position peaked at $26.2M in Q1 2022. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Morgan Stanley held 184,192 shares of Fulcrum Therapeutics worth $674K as of Q2 2026.
  • Morgan Stanley bought 10,855 Fulcrum Therapeutics shares in Q2 2026, an estimated $66K.
  • Fulcrum Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5414 holding.
  • Morgan Stanley first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • Morgan Stanley's Fulcrum Therapeutics position peaked at $26.2M in Q1 2022.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.